|
注册号: Registration number: |
ChiCTR2500104690 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-21 15:14:09 |
|
注册时间: Date of Registration: |
2025-06-20 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
新型DAMP分子的含量与脓毒症的相关关系研究 |
|
Public title: |
Study on the correlation between the content of novel DAMP molecule and sepsis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
新型DAMP分子的含量与脓毒症的相关关系研究 |
|
Scientific title: |
Study on the correlation between the content of novel DAMP molecule and sepsis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
付乐 |
研究负责人: |
罗亮 |
|
Applicant: |
Le Fu |
Study leader: |
Liang Luo |
|
申请注册联系人电话: Applicant telephone: |
+86 130 6873 6929 |
研究负责人电话:
Study leader's |
+86 137 2515 0091 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
fule3@mail.sysu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
luoliang@mail.sysu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
深圳市光明区新湖街道圳园路628号 |
研究负责人通讯地址: |
深圳市光明区新湖街道圳园路628号 |
|
Applicant address: |
No.628, Zhenyuan Rd, Guangming (New) Dist., Shenzhen, China, 518107 |
Study leader's address: |
No.628, Zhenyuan Rd, Guangming (New) Dist., Shenzhen, China, 518107 |
|
申请注册联系人邮政编码: Applicant postcode: |
518107 |
研究负责人邮政编码: Study leader's postcode: |
518107 |
|
申请人所在单位: |
中山大学附属第七医院(深圳) |
||
|
Applicant's institution: |
The Seventh Affiliated Hospital, Sun Yat-sen University |
||
|
研究负责人所在单位: |
中山大学附属第七医院(深圳) |
||
|
Affiliation of the Leader: |
The Seventh Affiliated Hospital, Sun Yat-sen University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY-2022-067-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中山大学附属第七医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the Seventh Affiliated Hospital, Sun Yat-sen University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-10-11 00:00:00 | ||
|
伦理委员会联系人: |
魏嘉艺 |
||
|
Contact Name of the ethic committee: |
Jiayi Wei |
||
|
伦理委员会联系地址: |
深圳市光明区新湖街道圳园路628号 |
||
|
Contact Address of the ethic committee: |
No.628, Zhenyuan Rd, Guangming (New) Dist., Shenzhen, China, 518107 |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 137 5059 0729 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
weijiayi@sysush.com |
|
研究实施负责(组长)单位: |
中山大学附属第七医院(深圳) |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
The Seventh Affiliated Hospital, Sun Yat-sen University |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
深圳市光明区新湖街道圳园路628号 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
No.628, Zhenyuan Rd, Guangming (New) Dist., Shenzhen, China |
||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
深圳市科技创新委员会基础研究(重点项目)(JCYJ20220818102017035) |
||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
Key basic research projects of Shenzhen Science and Technology Innovation Commission (JCYJ20220818102017035) |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
脓毒症 |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Sepsis |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
本研究计划以脓毒症患者、病原感染性疾病患者为主要研究对象,针对本合作团队成员原创发现的一类新型DAMP类炎症因子,检测病患体液中(包括血清或血浆、尿液、脑脊液等。目前可以以血清样本检测为首要目标)此类新型炎症因子的含量,分析新型炎症因子与脓毒症和病原感染患者发病状况的相关性,分析新型炎症因子的检测在此类病患的(1)早期临床诊断、(2)病程监控、以及(3)预后判断等方面的临床应用潜能,探索其被应用于相关疾病临床检测的价值。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
This study plans to take patients with sepsis and patients with pathogenic infectious diseases as the main research objects. Aiming at a new type of DAMP-like inflammatory factor originally discovered by the members of the cooperative team, detect the inflammatory factors in the patient's body fluids (including serum or plasma, urine, and cerebrospinal fluid). etc. At present, serum samples can be used as the primary target to detect the content of such new inflammatory factors, analyze the correlation between new inflammatory factors and the onset status of patients with sepsis and pathogenic infection, and analyze the effect of the detection of new inflammatory factors on such patients (1) Clinical application potential of early clinical diagnosis, (2) disease course monitoring, and (3) prognosis judgment, etc., and explore its value in clinical detection of related diseases. |
||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
1.未满足上述入选标准的样本; 2.样本收集/保存不当不能用于检测者; 3.检测前发生样本污染。 4.孕产妇; 5.临床资料不完善者。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
1. Samples that do not meet the above inclusion criteria; 2. Improper collection/storage of samples that cannot be used for testing; 3. Sample contamination occurs prior to testing. 4. Maternity; 5. Those with incomplete clinical data. |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-01-01 00:00:00至 To 2024-10-27 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-01-04 00:00:00 至 To 2024-10-27 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
文章发表后6个月内在临床试验公共管理平台上传数据,网址www.medresman.org |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The data will be uploaded on the clinical trial public management platform within 6 months after the publication of the article, and the URL is www.medresman.org |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |